• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Type-2 Diabetes Mellitus: A Review of Current Trends
  • VIEWS 857
  • PDF 215

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v21i4.22.21

Year: 2022, Volume: 21, Issue: 4, Pages: 95-104

Systematic Review

Type-2 Diabetes Mellitus: A Review of Current Trends

Priya Patel​ ✉ 1 , Hiren Patel 1 , Hiren Bhagiya 1 , Bhavisha Kacha 1 , Austin Christian 1

1 Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujrat­, 360005, India

Corresponding author ✉: [email protected]

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Diabetes mellitus type 2 is a chronic metabolic condition whose incidence has been continuously growing around the world. As a result of this tendency, it is quickly becoming an epidemic in some parts of the world, with the number of individuals affected anticipated to double in the next decade as the world's population ages, adding to the already existing load on healthcare providers, particularly in poor developing countries. World Health Organization (WHO) guidelines are still used for screening and diagnosis, which include both clinical and laboratory characteristics. There is currently no cure for the disease; however, therapy options include lifestyle changes, obesity management, oral hypoglycemic medications, and insulin sensitizers such as metformin, a biguanide that reduces insulin resistance which is used as first line medication especially for obese patients. The traditional herbal medicine like garlic, neem, bitter gourd, aloe vera, onion, methi, amla, jamun, baheda etc. are also used for the treatment of the diabetes. Other effective medication includes non-sulfonylurea secretagogues, thiazolidinediones, alpha glucoside inhibitors, and insulin. Recent research into the biology of type 2 diabetes has led to the development of new medications such as glucagon-like peptide 1 analogues: dipeptidyl peptidase inhibitors, sodium glucose cotransporter 2 inhibitors, and 11-hydroxysteroid dehydrogenase 1 inhibitors, insulin releasing glucokinase activators. The novel drug delivery improves the treatment of diabetes by the inhaled insulin.

 

Keywords: Type 2 diabetes mellitus, Diabetes complications, Diabetes diagnosis, Diabetes management, Antidiabetic newer drugs, Antidiabetic herbal drugs

References

  1. Kumar CR. Basic Pathology (5). (pp. 569-587) Bangalore. Prism Book Private Limited. 1992.
  2. Waugh A, Grant A. Ross & Wilson Anatomy and Physiology in Health and Illness (11). (pp. 227-229) Churchill Livingstone Elsevier. 2010.
  3. Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. Journal of Clinical Investigation. 2006;116(6):1713–1722. Available from: https://doi.org/10.1172%2FJCI25112
  4. Wassmuth R, Lernmark Å. The genetics of susceptibility to diabetes. Clinical Immunology and Immunopathology. 1989;53(3):358–399. Available from: https://doi.org/10.1016/0090-1229(89)90002-0
  5. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. The Lancet. 2001;358(9277):221–229. Available from: https://doi.org/10.1016/s0140-6736(01)05415-0
  6. Jun SK, Yoon YW. A new look at viruses in type 1 diabetes. Diabetes Metabolism Research and Reviews. 2002;19(1):8–31. Available from: https://doi.org/10.1002/dmrr.337
  7. Jecob LS, P. Pharmacology (The National medical series for independent study) (3). (pp. 221-225) Hong Kong, London. 1987.
  8. Tripathi KD. Essential medicals pharmacology (7). (pp. 258-281) Jaypee brothers medical publishers . 2013.
  10. Harris MI. Undiagnosed NIDDM: Clinical and Public Health Issues. Diabetes Care. 1993;16(4):642–652. Available from: https://doi.org/10.2337/diacare.16.4.642
  11. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2014;37(Supplement_1):S81–S90. Available from: https://doi.org/10.2337/dc14-S081
  12. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes. 1996;45(7):926–933. Available from: https://doi.org/10.2337/diab.45.7.926
  13. Kahn CR, Lecture B. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes. 1994;43(8):1066–1084. Available from: https://doi.org/10.2337/diab.43.8.1066
  14. Paul RR. Antagonist: diabetes and insulin resistance--philosophy, science, and the multiplier hypothesis. The Journal of laboratory and clinical medicine. 1995;125(5):560–564. Available from: https://pubmed.ncbi.nlm.nih.gov/7738421/
  17. DGS, DG. Greenspan’s Basic & Clinical Endocrinology (9). The McGraw-Hill Companies. 2011.
  18. Barrett KE, Barman SM, Brooks HL, Yuan JXJ. Ganong’s Review of Medical Physiology (24). 2012.
  19. Murray RK, Granner DK, Mayes PA, Rodwell VW. Harper’s Illustrated Biochemistry (29). (pp. 978-985) McGraw-Hill Medical. 2012.
  20. Bloom A, Hayes TM, Gamble DR. Register of newly diagnosed diabetic children. Br Med J. 1975;3(5983):580–583.
  21. Alemu S, Dessie A, Seid E, Bard E, Lee PT, Trimble ER, et al. Insulin-requiring diabetes in rural Ethiopia: should we reopen the case for malnutrition-related diabetes? Diabetologia. 2009;52(9):1842–1845. Available from: https://doi.org/10.1007/s00125-009-1433-5
  22. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. Available from: https://doi.org/10.2337/diacare.27.5.1047
  23. Gupta OP, Joshi MH, Dave SK. Prevalence of diabetes in India. Adv Metab Disord. 1978;9:147–165. Available from: https://doi.org/10.1016/B978-0-12-027309-6.50013-6
  24. Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician. 2009;79(1):29–36. Available from: https://pubmed.ncbi.nlm.nih.gov/19145963/
  25. Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345(11):790–797. Available from: https://doi.org/10.1056/nejmoa010492
  28. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet. 2005;366(9491):1059–1062. Available from: https://doi.org/10.1016/s0140-6736(05)67402-8
  29. Powers AC. Diabetes mellitus. In: Fauci AS, Braunwauld E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., eds. Harrison’s Principles of Internal Medicine (17). (pp. 2275-2304) 2008.
  30. Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol. 2011;26(4):342–349. Available from: https://doi.org/10.1097%2FHCO.0b013e3283470359
  31. Izzedine H, Launay-Vacher V, Deybach C, Bourry E, Barrou B, Deray G. Drug-induced diabetes mellitus. Expert Opin Drug Saf. 2005;4(6):1097–1109. Available from: https://doi.org/10.1517/14740338.4.6.1097
  34. Adeyinka A, Kondamudi NP. Hyperosmolar Hyperglycemic Syndrome. In: StatPearls. StatPearls Publishing. 2022.
  36. Kobayashi S, Liang Q. Autophagy and mitophagy in diabetic cardiomyopathy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2015;1852(2):252–261. Available from: https://doi.org/10.1016/j.bbadis.2014.05.020
  37. Chiniwala N, Jabbour S. Management of diabetes mellitus in the elderly. Current Opinion in Endocrinology. 2011;18(2):148–152. Available from: https://doi.org/10.1097/med.0b013e3283444ba0
  38. Asif AH, Nanjundan PK, Basavarajappa GM, Sreeharsha N. Uma Chandur and Teeka Srinivasasetty Roopashree. Insulin Resistance Modulation with Lifestyle Modification - Proof of Concept - Study in Rats. Indian Journal of Pharmaceutical Education and Research. 2020;54(4):999–1006. Available from: https://doi.org/10.5530/ijper.54.4.173
  39. Collier CA, Bruce CR, Smith AC, Lopaschuk G, Dyck DJ. Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle. Am J Physiol Endocrinol Metab. 2006;291(1):E182–E189. Available from: https://doi.org/10.1152/ajpendo.00272.2005
  40. Staa TV, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 1997;50(6):735–741. Available from: https://doi.org/10.1016/S0895-4356(97)00024-3
  41. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Archives of Internal Medicine. 1997;157(15):1681–1686. Available from: https://pubmed.ncbi.nlm.nih.gov/9250229/
  43. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, Mackay P, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes. 1998;47(3):345–351. Available from: https://doi.org/10.2337/diabetes.47.3.345
  45. Yki-Järvinen H. 47.Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106–1124. Available from: https://doi.org/10.1056/nejmra041001
  46. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681–1689. Available from: https://doi.org/10.1016/s0140-6736(06)69703-1
  49. Martin JH, Deacon CF, Gorrell MD, Prins JB. Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience. Intern Med J. 2011;41(4):299–307. Available from: https://doi.org/10.1111/j.1445-5994.2011.02439.x
  50. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007;23(4):919–950. Available from: https://doi.org/10.1185/030079906x162746
  52. Burge MR, Schade DS. INSULINS. Endocrinology and Metabolism Clinics of North America. 1997;26(3):575–598. Available from: https://doi.org/10.1016/s0889-8529(05)70268-1
  53. Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. Canadian Medical Association Journal. 2009;180(4):400–407. Available from: https://doi.org/10.1503%2Fcmaj.081180
  54. Tahrani AA, Bailey CJ, Prato D, Barnett S, AH. Management of type 2 diabetes: new and future developments in treatment. Lancet. 2011;378(9786):182–197. Available from: https://doi.org/10.1016/s0140-6736(11)60207-9
  55. Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. J Ethnopharmacol. 2002;81(1):81–100. Available from: https://doi.org/10.1016/S0378-8741(02)00059-4
  56. Seth SD, Sharma B. Medicinal plants in India. Indian J Med Res. 2004;120(1):9–11. Available from: https://pubmed.ncbi.nlm.nih.gov/15299226/
  57. Li WL, Zheng HC, Bukuru J, Kimpe ND. Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol. 2004;92(1):1–21. Available from: https://doi.org/10.1016/j.jep.2003.12.031
  58. Wadood A, Wadood N, Shah SA. Effects of Acacia arabica and Caralluma edulis on blood glucose levels of normal and alloxan diabetic rabbits. J Pak Med Assoc. 1989;39(8):208–212.
  59. Roman-Ramos R, Flores-Saenz JL, Alarcon-Aguilar FJ. Anti-hyperglycemic effect of some edible plants. Journal of Ethnopharmacology. 1995;48(1):25–32. Available from: https://doi.org/10.1016/0378-8741(95)01279-m
  60. Kumari K, Mathew BC, Augusti KT. Antidiabetic and hypolipidemic effects of S-methyl cysteine sulfoxide isolated from Allium cepa Linn. Indian J Biochem Biophys. 1995;32(1):49–54. Available from: https://pubmed.ncbi.nlm.nih.gov/7665195/
  62. Sheela CG, Augusti TK. Antidiabetic effects of S-allyl cysteine sulphoxide isolated from garlic Allium sativum Linn. Indian Journal of Experimental Biology. 1992;30:523–526. Available from: https://pubmed.ncbi.nlm.nih.gov/1506036/
  64. Ali L, Kalam, Khan, Hassan M, Mosihuzzaman, Nahar, et al. Characterization of the hypoglycemic effects of Trigonella foenum graecum seed. Planta Medica. 1995;61(4):358–360. Available from: https://doi.org/10.1055/s-2006-958100
  65. Al-Awadi FM, Gumaa KA. Studies on the activity of individual plants of an antidiabetic plant mixture. Acta Diabetol Lat . 1987;24(1):37–41. Available from: https://doi.org/10.1007/bf02732051
  66. Ajabnoor MA. Effect of aloes on blood glucose levels in normal and alloxan diabetic mice. Journal of Ethnopharmacology. 1990;28(2):215–220. Available from: https://doi.org/10.1016/0378-8741(90)90031-n
  67. Davis RH, Maro NP. Aloe vera and gibberellins, Anti-inflammatory activity in diabetes. J. Am. Pediat. Med. Assoc. 1989;79(1):24–26. Available from: https://doi.org/10.7547/87507315-79-1-24
  68. Chattopadhyay RR, Chattopadhyay RN, Nandy AK, Poddar G, Maitra SK. Preliminary report on antihyperglycemic effect of fraction of fresh leaves of Azadiracta indica (Beng neem) Bull. Calcutta. Sch. Trop. Med. 1987;35:29–33.
  69. Chattopadhyay RR, Chattopadhyay RN, Nandy AK, Poddar G, Maitra SK. The effect of fresh leaves of Azadiracta indica on glucose uptake and glycogen content in the isolated rat hemidiaphragm. Bull. Calcutta. Sch. Trop. Med. 1987;35:8–12. Available from: https://www.scienceopen.com/document?vid=12408c04-deca-4427-9c72-81d6b188c0af
  70. Biswas K, Chattopadhyay I, Banerjee RK, Bandyopadhyay U. Biological activities and medicinal properties of neem (Azadiracta indica) Curr. Sci. 2002;82(11):1336–1345. Available from: https://www.jstor.org/stable/24106000
  74. Ganji SR, Mahboubeh R, Hamed K, Kumar P, Kumar D, Pradeep K, et al. Antinociceptive Effect of Terminalia bellirica in Diabetic Peripheral Neuropathy: a Comparison with Fluoxetin, Imipramine and Quercetin. Lat Am J Pharm. 2012;31(4):520–525.
  76. Kohli S, Kumar PN. Combined effect of Coccinia indica leaf extract with acarbose in type II diabetes induced neuropathy in rats. J. Innov. Pharm. Biol. Sci. 2014;2014(1):77–87.
  77. Premkumar N, Annamalai AR, Thakur &RS. Antinociceptive property of Emblica officinalis Gaertn (Amla) in high fat diet - fed/low dose streptozotocin induced diabetic neuropathy in rats. Indian Journal of Experimental Biolpgy. 2009;47(9):737–742. Available from: https://pubmed.ncbi.nlm.nih.gov/19957886/
  79. Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375(9733):2244–2253. Available from: https://doi.org/10.1016/s0140-6736(10)60632-0

Copyright

 

© 2022 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/) 

  • 04 March 2023

Year: 2022, Volume: 21, Issue: 4


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.